Dr. Wei Jia’s Team Achieves Fruitful Results on EHA 2023

Dr. Wei Jia’s Team Achieves Fruitful Results on EHA 2023

2024.01.26
From June 8th to 11th, the 28th European Hematology Association (EHA) Annual Congress was held in a combined online and offline format in Frankfurt, Germany. Top global experts in hematology shared various scientific themes, clinical and basic research, discussing cutting-edge achievements. Dr. Wei Jia’s team, currently stationed at Tongji Shanxi Hospital, Director of the Hematology Department at Shanxi Baiqiu'en Hospital, China, had three research results selected for presentation. Oncology Frontier specially invited Dr. Wei to present the findings.
Dr. Huang Huiqiang: Immune Therapy Era is Imminent for Extranodal NK/T Cell Lymphoma

Dr. Huang Huiqiang: Immune Therapy Era is Imminent for Extranodal NK/T Cell Lymphoma

2024.01.25
Extranodal NK/T cell lymphoma (ENKTCL), nasal type, is a rare subtype prevalent in Asian populations and associated with the Epstein-Barr virus (EBV). Currently, patients' prognosis remains poor, especially for relapsed/refractory (R/R) cases. From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany. A selected oral presentation (Abstract No: S226) revealed significant efficacy in treating R/R ENKTCL patients with PD-1 inhibitors alone or in combination. This study once again confirms that immune checkpoint inhibitors have become a crucial therapeutic approach for R/R ENKTCL patients. Oncology Frontier had the privilege of inviting Dr. Huang Huiqiang from Sun Yat-sen University Cancer Center, China, to share the results and insights from this research at the conference.
Dr. Hou Ming: BTK Inhibitor Ibrutinib Offer Limitless Prospects for ITP Treatment

Dr. Hou Ming: BTK Inhibitor Ibrutinib Offer Limitless Prospects for ITP Treatment

2024.01.25
Editor's Note: From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Congress was held in Frankfurt, Germany. During this conference, Dr. Hou Ming's team at Qilu Hospital, Shandong University, China, presented the research findings on the use of the BTK inhibitor ibrutinib for primary immune thrombocytopenia (ITP) (abstract S299). To gain deeper insights into this study and its implications for the current status of ITP treatment, Oncology Frontier had an exclusive interview with Dr. Hou Ming. He provided a detailed overview of the current situation of ITP treatment in China and the promising future of using BTK inhibitors for ITP therapy.